#159 ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy+ bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis
Andrew R. Clamp, Jonathan A. Ledermann(London Cancer), Adrian Cook(University College London), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Francesca Schiavone(MRC Clinical Trials Unit at UCL), Axel Walther, Audrey Cook(University College London), Sharadah Essapen(Royal Surrey County Hospital), Aleksandra Gentry‐Maharaj(UCL Australia), James D. Brenton(Cambridge University Hospitals NHS Foundation Trust), Richard Kaplan(University College London), Sudha Sundar(Sandwell & West Birmingham Hospitals NHS Trust), Roshan Agarwal(Imperial College Healthcare NHS Trust), Sarah P. Blagden(Churchill Hospital), Cristiana Sessa(Institute of Oncology Research), Iain A. McNeish(Imperial College London), Domenico Radice(University College London), Rosemary Lord(Clatterbridge Cancer Centre NHS Foundation Trust), Dearbhaile M. O’Donnell, Mahesh Parmar(University College London)
Cited by 4
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k